Cogent Biosciences, Inc. COGT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $282.12M+16.1% | $269.78M+16.0% | $256.27M+16.8% | $250.89M+21.9% | $242.98M+27.6% | ||
| $79.92M+75.7% | $63.58M+46.9% | $51.34M+24.9% | $48.77M+25.9% | $45.49M+23.4% | ||
| $362.04M+25.5% | $333.36M+20.8% | $307.6M+18.1% | $299.66M+22.5% | $288.47M+26.9% | ||
| -$362.04M-25.5% | -$333.36M-20.8% | -$307.6M-18.1% | -$299.66M-22.5% | -$288.47M-26.9% | ||
| $4.28M— | $3.06M— | —— | —— | —— | ||
| $19.35M+13.9% | $14.69M-18.8% | $13.07M-27.8% | $13.96M-20.3% | $16.98M+14.2% | ||
| —— | —— | $13.23M-27.0% | $15.59M-11.2% | $18.97M+25.4% | ||
| —— | -$7.18M— | -$5.39M— | -$3.59M— | -$1.8M— | ||
| -$354.3M-31.5% | -$328.94M-28.6% | -$294.37M-21.5% | -$284.08M-25.1% | -$269.5M-27.0% | ||
| -$2.17-10.2% | -$2.16-11.3% | -$2.05-28.9% | -$2.07-21.1% | -$1.97-5.3% | ||
| -$2.17-10.2% | -$2.16-11.3% | -$2.05-28.9% | -$2.07-21.1% | -$1.97-5.3% | ||
| 543.1M+27.3% | 494.2M+21.1% | 469.2M+22.2% | 441.8M+22.8% | 426.6M+27.2% | ||
| 543.1M+27.3% | 494.2M+21.1% | 469.2M+22.2% | 441.8M+22.8% | 426.6M+27.2% | ||
| -$354.88M-31.8% | -$329.03M-28.7% | -$295.06M-22.3% | -$283.87M-25.0% | -$269.29M-26.9% | ||
| —— | —— | —— | —— | $0+100% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$155K-108% | -$20K-101% | $1.93M+4,295% | $1.94M+4,407% | $1.99M+645% | ||
| -$362.04M-25.5% | -$333.36M-20.8% | -$307.6M-18.1% | -$299.66M-22.5% | -$288.47M-26.9% | ||
| -$359.47M-25.7% | -$330.79M-20.9% | -$305.06M-18.2% | -$297.14M-22.7% | -$285.99M-27.1% | ||
| -$359.47M-25.7% | -$330.79M-20.9% | -$305.06M-18.2% | -$297.14M-22.7% | -$285.99M-27.1% | ||
| -$362.04M-25.5% | -$333.36M-20.8% | -$307.6M-18.1% | -$299.66M-22.5% | -$288.47M-26.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cogent Biosciences, Inc.'s revenue?
- Cogent Biosciences, Inc. (COGT) generated $7.9M in revenue over the trailing twelve months, down 65.0% year over year.
- Is Cogent Biosciences, Inc. profitable?
- Cogent Biosciences, Inc. is not currently profitable: it reported a net loss of $354.3M over the trailing twelve months, a -950.4% net margin.
- What is Cogent Biosciences, Inc.'s earnings per share?
- Cogent Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-2.17.
- Where does Cogent Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
